RemeGen Co Ltd Class H 09995
Trading Information
- Previous Close Price
- HK$17.74
- Day Range
- HK$16.88–20.40
- 52-Week Range
- HK$10.20–49.00
- Bid/Ask
- HK$20.20 / HK$20.25
- Market Cap
- HK$10.99 Bil
- Volume/Avg
- 3.7 Mil / 2.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.18
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 3,497
- Website
- https://www.remegen.com
Comparables
Valuation
|
Metric
|
09995
|
02509
|
6617
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.84 | 32.68 | 4.46 |
Price/Sales | 7.18 | 100.25 | 415.65 |
Price/Cash Flow | — | — | — |
Price/Earnings
09995
02509
6617
Financial Strength
|
Metric
|
09995
|
02509
|
6617
|
|---|---|---|---|
Quick Ratio | 0.88 | 1.70 | 10.19 |
Current Ratio | 1.51 | 1.86 | 10.28 |
Interest Coverage | −31.92 | −18.42 | −39.00 |
Quick Ratio
09995
02509
6617
Profitability
|
Metric
|
09995
|
02509
|
6617
|
|---|---|---|---|
Return on Assets (Normalized) | −25.68% | −47.40% | −4.63% |
Return on Equity (Normalized) | −42.27% | −341.08% | −5.29% |
Return on Invested Capital (Normalized) | −29.27% | −56.34% | −6.89% |
Return on Assets
09995
02509
6617
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Gfzdgbyt | Yrng | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Tdspwqx | Xzslpk | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dkxkjgsq | Vjgjqt | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Dttjffqd | Zkqhv | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Ygfwxmp | Gcbnr | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Yjjmdvn | Fthq | $29.2 Bil | |||
| Moderna Inc
MRNA
| Fpqjcfxr | Msrz | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Kcbvfnklx | Prjgd | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Kjnbqmbb | Jgdddt | $13.2 Bil | |||
| Incyte Corp
INCY
| Dzfbdzwx | Rlkxkfd | $13.0 Bil |
United States